Pomalyst

Acquired Immunodeficiency Syndrome, HIV Vaccine, Multiple Myeloma + 2 more
Treatment
4 FDA approvals
17 Active Studies for Pomalyst

What is Pomalyst

PomalidomideThe Generic name of this drug
Treatment SummaryPomalidomide is a medication that helps to modulate the immune system and fight cancerous cells. It is a type of thalidomide and was approved by the FDA in 2013.
Pomalystis the brand name
image of different drug pills on a surface
Pomalyst Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Pomalyst
Pomalidomide
2013
4

Approved as Treatment by the FDA

Pomalidomide, otherwise known as Pomalyst, is approved by the FDA for 4 uses including Multiple Myeloma (MM) and Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor .
Multiple Myeloma (MM)
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone
Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor
Used to treat Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor in combination with Dexamethasone
Multiple Myeloma
Used to treat Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor in combination with Dexamethasone
Multiple Myeloma
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone

Effectiveness

How Pomalyst Affects PatientsPomalidomide is much stronger than thalidomide and lenalidomide, being 100 times and 10 times more potent than them, respectively.
How Pomalyst works in the bodyPromalidomide is a drug that helps fight cancer. It stops the growth and death of tumor cells. It also boosts the immune system by aiding T cells and natural killer cells in fighting off infections. Promalidomide works by binding to a specific protein called cereblon, which prevents it from working properly, and also inhibits an enzyme called COX2.

When to interrupt dosage

The advised portion of Pomalyst is contingent upon the specified condition. The dosage fluctuates, in line with the technique of delivery (e.g. Oral or Capsule) noted in the table beneath.
Condition
Dosage
Administration
Multiple Myeloma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
HIV Vaccine
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Acquired Immunodeficiency Syndrome
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Kaposi Sarcoma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Multiple Myeloma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral

Warnings

There are 20 known major drug interactions with Pomalyst.
Common Pomalyst Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Antilymphocyte immunoglobulin (horse).
Azelastine
Major
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Pomalidomide.
Pomalyst Toxicity & Overdose RiskCommon side effects of taking this drug include feeling tired or weak, low levels of white blood cells, low levels of red blood cells, constipation, nausea, diarrhea, difficulty breathing, upper respiratory infections, back pain, and fever.
image of a doctor in a lab doing drug, clinical research

Pomalyst Novel Uses: Which Conditions Have a Clinical Trial Featuring Pomalyst?

17 active trials are currently being conducted to investigate the effectiveness of Pomalyst in managing Refractory Multiple Myeloma.
Condition
Clinical Trials
Trial Phases
Kaposi Sarcoma
7 Actively Recruiting
Phase 1, Phase 2
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Multiple Myeloma
0 Actively Recruiting
HIV Vaccine
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
4 Actively Recruiting
Phase 1, Phase 2, Not Applicable

Pomalyst Reviews: What are patients saying about Pomalyst?

5Patient Review
1/15/2020
Pomalyst for Multiple Myeloma
I've been using this treatment since December 2016 for my aggressive myeloma. It's worked much better than Vecade and Cytoxin, and I haven't had a relapse in over three years.
3.7Patient Review
8/14/2015
Pomalyst for Multiple Myeloma
I now have a blood clot in my right lung. I have been on the drug for over a year.
3.3Patient Review
2/22/2018
Pomalyst for Multiple Myeloma
I took this medication for my second outbreak of multiple myeloma, which did help lower my light chains. However, I still developed plasma cytoma in my left arm and had to receive radiation treatment as a result. After trying this again during my maintenance chemotherapy, there was only a temporary lowering of the light chains before they increased 16%. Next month, I'll be trying a different medication.
3.3Patient Review
3/22/2013
Pomalyst for Multiple Myeloma
This medication really irritates my stomach.
2.7Patient Review
6/10/2014
Pomalyst for Multiple Myeloma
The side effects were pretty bad. I developed open lesions inside my vagina and anus.
1Patient Review
4/14/2013
Pomalyst for Multiple Myeloma
I had a severe reaction to this medication, including an itchy rash, swelling of the face, and pain.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pomalyst

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Pomalyst a chemo drug?

"Pomalyst is the trade name for the generic chemotherapy drug pomalidomide, which may also be referred to by health care professionals as the generic drug name."

Answered by AI

Is Pomalyst stronger than Revlimid?

"The drug Pomalyst, also known as pomalidomide, is an oral immunomodulatory agent that is similar to Revlimid and Thalomid, but more potent. Pomalyst is manufactured by Celgene."

Answered by AI

What is Pomalyst used for?

"POMALYST, in combination with dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including a proteasome inhibitor and lenalidomide. POMALYST should be used in patients whose disease has progressed on or within 60 days of completion of their last therapy"

Answered by AI

What type of medication is Pomalyst?

"Pomalyst can be prescribed to help treat the symptoms of Multiple myeloma and Kaposi Sarcoma. It may be used on its own or in combination with other medications. Pomalyst is categorised as an Antineoplastic and Angiogenesis Inhibitor drug."

Answered by AI

Clinical Trials for Pomalyst

Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of Minnesota in Minneapolis, United States.

Propranolol for Kaposi Sarcoma

18+
All Sexes
Minneapolis, MN
Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the most commonly diagnosed cancers in many African countries where economic constraints prevent successful treatment in most patients. Treatment outcomes in developed countries are also often unsatisfactory in HIV positive patients despite good virological and immunological responses to antiretroviral therapy. Therefore, identification of new oral, safe treatment options for treatment of KS remains a research priority. Given the known anti-angiogenic properties and based on the treatment response with other benign vascular lesions such as infantile hemangioma, propranolol is a good candidate for the treatment of KS. The hypothesis of this study is that treating patients with Kaposi sarcoma with propranolol will result in an overall response rate (complete response rate plus partial response rate) of at least 45%, and that propranolol will be safe and well tolerated in this patient population.
Phase 2
Recruiting
University of Minnesota (+3 Sites)Lee Ratner, M.D., Ph.D.
Image of Abramson Cancer Center at University of Pennsylvania in Philadelphia, United States.

Limited-duration Teclistamab for Multiple Myeloma

18+
All Sexes
Philadelphia, PA
This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria, following 6 to 9 months of treatment with teclistamab, a B-cell maturation antigen (BCMA)-directed T-cell engager (anti-BCMAxCD3 bispecific antibody), will be offered monitored drug discontinuation. Teclistamab is typically dosed on a regular schedule (every 1-4 weeks) indefinitely until disease progression ("continuous therapy"). Here, a limited-duration regimen will be studied in which patients achieving ≥VGPR after 6-9 months of standard teclistamab dosing will discontinue therapy and resume if laboratory or clinical parameters suggest early disease progression ("limited-duration therapy"). Patients will enter the clinical trial protocol after completing 6-9 months of standard teclistamab monotherapy and achieving ≥VGPR. The study's hypothesis is that the failure probability six months after stopping teclistamab in this patient population will be non-inferior compared to that of historical controls treated with continuous therapy. Reducing drug exposure may be beneficial by reducing risk of infection and reducing anti-BCMA selective pressure toward generation of BCMA-negative relapses. Analysis of minimal residual disease (MRD), tumor features, and bone marrow microenvironment parameters, which will be pursued as exploratory correlative analyses in this study, may identify factors that predict durable response to limited-duration therapy and thereby enable more precise selection of patients likely to benefit from this approach. A subset of patients will be enrolled on a biomarker study for analysis of these exploratory endpoints.
Phase 2
Recruiting
Abramson Cancer Center at University of Pennsylvania (+4 Sites)Alfred Garfall, MD
Have you considered Pomalyst clinical trials? We made a collection of clinical trials featuring Pomalyst, we think they might fit your search criteria.Go to Trials
Image of Columbia University Irving Medical Center in New York, United States.

WiseApp for HIV

18+
All Sexes
New York, NY
This study aims to conduct a 12-month randomized controlled trial to adapt the mobile app, WiseApp, and a smart pill dispenser for Spanish-speaking people living with HIV (PLWH) in the New York City (NYC) area and La Romana, Dominican Republic (DR). The study will assess the efficacy and sustainability of WiseApp as well as identify barriers with its widespread use among Spanish speakers. With disproportionately high rates of HIV in the New York City area and the Dominican Republic, this project seeks to identify distinct contextual factors related to Spanish speaking people living with HIV and increase the likelihood of engagement with technology and improvements in clinical outcomes.
Recruiting
Has No Placebo
Columbia University Irving Medical CenterRebecca Schnall, PhD, MPH
Image of National Institutes of Health Clinical Center in Bethesda, United States.

Abemaciclib for Kaposi Sarcoma

18+
All Sexes
Bethesda, MD
Background: Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV. KS tumors usually involve the skin, but may also involve lymph nodes, lungs, bone, and gastrointestinal tract. Researchers want to see if a drug that is currently used to treat a type of breast cancer can help. Objective: To find a safe dose of abemaciclib to treat KS and to see if it can shrink lesions or tumors. Eligibility: People ages 18 and older with KS. Design: Participants will be screened with some or all of the following: Medical history Physical exam Blood and urine tests Chest x-ray and/or computed tomography scans Lung or gastrointestinal tract exam with an endoscope (a flexible instrument to examine the interior of the organ) Medicine review Heart function tests KS lesion assessment Skin sample from a KS lesion Treatment will be given in 28-day cycles. Participants will take the study drug tablets by mouth everyday. They will keep a medicine diary. They will get the study drug until their cancer gets worse or they have unacceptable side effects. Participants will have a study visit at the beginning of each cycle. At these visits, they will repeat some screening tests. They may have medical photographs taken of body surfaces. They may complete questionnaires about their quality of life. They may give skin and saliva samples. For skin samples, an area of skin will be numbed. A small circle of skin over an area affected by KS will be removed. Participants will have follow-up visits for up to 2 years after treatment ends.
Phase 1 & 2
Recruiting
National Institutes of Health Clinical CenterRamya M Ramaswami, M.D.
Have you considered Pomalyst clinical trials? We made a collection of clinical trials featuring Pomalyst, we think they might fit your search criteria.Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

NHS-IL12 + M7824 for Kaposi Sarcoma

18 - 99
All Sexes
Bethesda, MD
Background: Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among people living with HIV or those with prior history of transplant. Researchers want to see if 2 non-chemotherapy drugs can help people with KS. NHS-IL12 triggers the immune system to fight tumors. M7824 blocks the pathways that cancer cells use to stop the immune system from fighting tumors. Objective: To learn if giving NHS-IL12 alone or with M7824 could help the immune system fight KS tumors. Eligibility: People 18 and older with KS that has been treated with chemotherapy or immunotherapy Design: Participants will be screened with some or all of the following: medical history physical exam chest X-ray computed tomography scan blood and urine tests electrocardiogram and echocardiogram skin KS lesion biopsy lung exam gastrointestinal exam All participants will get NHS-IL12 every 4 weeks for up to 96 weeks (or 24cycles). It is injected under the skin. Some participants will also get M7824 every 2 weeks for up to 96 weeks (or 24cycles). It is given through a plastic tube that is put in an arm vein. Participants will complete questionnaires about how KS affects their quality of life. Their KS lesions will be measured and photographed. They will repeat some of the screening tests. They will give saliva samples or additional tissue samples. They will have a lung function test. Their ability to perform their normal activities will be assessed. The treatment duration is up to 96 weeks (or 24cycles) with an option to take NHS-IL12 and/or M7824 until the KS tumors are not responding, or you develop unacceptable side effects. Participants will have follow-up visits 7 and 30 days after treatment ends, then every 3 to 6 months for the next 18 months, then once a year for 3 years.
Phase 1 & 2
Recruiting
National Institutes of Health Clinical CenterRamya M Ramaswami, M.D.
Image of Northern Light Eastern Maine Medical Center in Bangor, United States.

Quad Regimen for Multiple Myeloma

18 - 75
All Sexes
Bangor, ME
A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab. Patients will be randomized to either: Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy. Arm B: 12 cycles of lenalidomide, ixazomib, daratumumab and dexamethasone, followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 years maintenance therapy.
Phase 2
Waitlist Available
Northern Light Eastern Maine Medical Center (+12 Sites)Evanthia Galanis, MDJanssen Scientific Affairs, LLC
Have you considered Pomalyst clinical trials? We made a collection of clinical trials featuring Pomalyst, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security